Baxalta develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. Co. is also investing in new disease areas, including oncology, as well as emerging technology platforms, including gene therapy and biosimilars. Co.'s business consists of a portfolio of products serving patient needs in a variety of ways. Co.'s four groups consist of Hemophilia, Inhibitor Therapies, Immunoglobulin Therapies and BioTherapeutics. When considering the Baxalta Inc stock dividend history, we have taken known splits into account, such that the BXLT dividend history is presented on a split-adjusted ("apples to apples") basis. Baxalta Inc dividend history is presented both in graphical/chart form, and as a BXLT dividend history data table along the right-hand column.
|
BXLT Stock Dividend HistoryThe BXLT dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable BXLT historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the BXLT dividend history record. Also see the BXLT stock dividend history data table along the right-hand column below. |
|
BXLT Next Dividend Date » (Projection based upon history) Quotes delayed 20 minutes |
Buy (3.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
Projection: BXLT Next Dividend Date Chart: BXLT Chart - 5Yr Dividend Yield |